Clinical trial
Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design
NCT02767063 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design
- Lead sponsor
- Versailles Hospital
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- July 31, 2016
- Completion date
- June 30, 2028
- Enrollment
- 100 (estimated)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.